Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $13.5 · 4 analysts
Stored first · Google News · Yahoo Finance (English)
Journey Medical Corporation $DERM Shares Sold by Opaleye Management Inc. - MarketBeat
Journey Medical Corporation $DERM Shares Sold by Opaleye Management Inc. MarketBeat
Journey Medical Corporation to Participate in September 2026 Investor Conferences - GlobeNewswire
Journey Medical Corporation to Participate in September 2026 Investor Conferences GlobeNewswire
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Journey Medical stock trades steadily as investors weigh small-cap dermatology potential - AD HOC NEWS
Journey Medical stock trades steadily as investors weigh small-cap dermatology potential AD HOC NEWS
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
536,000 Shares in Journey Medical Corporation $DERM Acquired by Punch & Associates Investment Management Inc. - marketbeat.com
536,000 Shares in Journey Medical Corporation $DERM Acquired by Punch & Associates Investment Management Inc. marketbeat.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | — | — | — | $18.37M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.18 | — | — | $13.14M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.8 | — | — | $42.51M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.69 | — | — | $27.89M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 26. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 25. | HC Wainwright & Co. | — | Initiate coverage | — → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 08. 14. | Lake Street | — | Maintain | Buy → Buy | — | Lake Street: Buy |
| 2025. 07. 31. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
| 2024. 02. 16. | Alliance Global Partners | — | Initiate coverage | — → Buy | — | Alliance Global Partners: Buy |
| 2023. 09. 07. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.
